Improving Cervical Cancer Screening for Women with HIV
This study, C-3002, aims to improve how women with Human Immunodeficiency Virus (HIV) get screened for cervical cancer and receive follow-up care. Researchers want to understand what makes it hard or easy for these women to get screened. They will do this by talking to women with HIV through in-depth interviews and by holding group discussions with healthcare team members. The study will also look at ways to use HPV (Human Papillomavirus) self-testing to increase screening. You may be able to join if you are a woman with HIV, between 25 and 49 years old, and eligible for cervical cancer screening. The goal is to find better ways to ensure women at higher risk for cervical cancer get the care they need.
- Study design
- This is an observational study involving about 3500 participants. It includes qualitative interviews with women and focus groups with healthcare teams.
- What's involved
- If you are a woman with HIV, you would participate in an in-depth qualitative interview. If you are a clinical team member, you would participate in a focus group.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will assess operational and logistical challenges at baseline and at a 1-month follow-up.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
C-3002: Enhancing Cervical Cancer Screening Access and Follow-up Care at 'CASCADE' Clinical Sites in the United States
At a glance
Conditions
Where it's being run
2 sites across 2 statesStudy leadership
- Jennifer S Smith, PhD · STUDY_CHAIR · University of North Carolina, Chapel Hill
- Lisa Rahangdale, MD, MPH · STUDY_CHAIR · University of North Carolina, Chapel Hill
- Clement S Adebamowo, ScD · PRINCIPAL_INVESTIGATOR · University of Maryland SOM
- Gregory Taylor, MD · PRINCIPAL_INVESTIGATOR · University of Maryland SOM
- Lisa Flowers, MD, MPH · PRINCIPAL_INVESTIGATOR · Emory University
- Anandi Sheth, MD, MSc · PRINCIPAL_INVESTIGATOR · Emory University
- Michael Hudgens, PhD · STUDY_DIRECTOR · University of North Carolina, Chapel Hill
- Katie Mollan, PhD · STUDY_DIRECTOR · University of North Carolina, Chapel Hill
- Vikrant Sahasrabuddhe, MBBS, MPH, DrPH · STUDY_DIRECTOR · Division of Cancer Prevention (DCP), NCI
- Laura Gaydos, PhD · STUDY_DIRECTOR · Emory University
- Patrick Ryscavage, MD · STUDY_DIRECTOR · University of Maryland SOM
- Sue Siminski · STUDY_DIRECTOR · Frontier Science Foundation
- Kayla Denson · STUDY_DIRECTOR · Frontier Science Foundation
- Nicole Freitag · STUDY_DIRECTOR · Frontier Science Foundation
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
What this trial measures
- Barriers and facilitators to cervical cancer screening and follow-up among women with HIVBaseline
Themes identified through semi-structured qualitative interviews assessing women with Human Immunodeficiency Virus (HIV) receiving care -reported barriers and facilitators to cervical cancer screening, adherence to follow-up care (including colposcopy and treatment), and perceptions of HPV self-collection approaches to improve screening uptake.
- Operational and logistical challenges that affect cervical cancer screening adherence and uptake of HPV self-testingBaseline and 1 month follow up
A University of North Carolina Chapel Hill Research Investigator will conduct in-depth interviews and the focus group discussions with clinical providers at Maryland and Georgia Clinical Sites for Aims 1b and 2. In Aim 1a, UNC will receive partially de-identified medical record data from the Clinical Sites to analyze data to evaluate cervical cancer screening cascade completion among women with Human Immunodeficiency Virus (HIV).